
ADI SOYADI: PINAR AKIN KABALAK 

BRANŞI: GÖĞÜS HASTALIKLARI

YABANCI DİLLER: İNGİLİZCE

İLETİŞİM: 05056836648

KLİNİK: PALYATİF BAKIM SERVİSİ

TIBBİ İLGİ VE UZMANLIK ALANLARI: GÖĞÜS HASTALIKLARI

EĞİTİMİ:

ANKARA ÜNİVERSİTESİ TIP FAKÜLTESİ 2001-2007

ANKARA ÜNİVERSİTESİ TIP FAKÜLTESİ GÖĞÜS HASTALIKLARI ABD: 2007-2013

ÇALIŞTIĞI KURUMLAR:

DÜZCE ATATÜRK DEVLET HASTANESİ: 2013 Mayıs-2014 Ocak

SANATORYUM HASTANESİ= 2014-HALEN

KASTAMONU DEVLET HASTANESİ: 26.1.2018-26.2.2018 (Geçici görev)

YAYINLAR:

1. Çiledağ A, **Akın Kabalak P**, Çelik G, Demir N, Yüksel C, Köycü G, Gökmen Öztuna D, Rad AY, Kaya A, Kutlay H, Savaş İ, Numanoğlu N. High serum YKL-40 level is associated with poor prognosis in patients with lung cancer. Tuberk Toraks. 2018 Dec;66(4):273-279. doi: 10.5578/tt.67319.
2. **Kabalak PA**, Savaş İ, Akar N, Demir N, Eğin Y. Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism. Pharmacogenomics J. 2018 Sep;18(5):646-651. doi: 10.1038/s41397-018-0037-1. Epub 2018 Aug 10
3. **Kabalak PA**, Esenkaya A. Severe Pneumonia Treated Succesfully with Levofloxacin and Oseltamivir During Flu Epidemic. Turk Thorac J. 2016 Apr;17(2):84-87. doi: 10.5578/ttj.17.2.018. Epub 2016 Apr 1.
4. **Akın Kabalak P**, Çiledağ A, Demir N, Çelik G, Yüksel C, Köycü G, Gökmen Öztuna D, Taner A, Kaya A, Kutlay H, Numanoğlu N, Savaş İ. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer. Tuberk Toraks. 2015 Jun;63(2):71-7.
5. Firat ND, Cıledağ A, **Kabalak PA**, Karnak D, Meco BC, Alanoğlu Z, Alkiş N. Pulmonary alveolar proteinosis and successful therapy with combined lavage procedures: Case reports Exp Ther Med. 2011 May;2(3):569-573. Epub 2011 Mar 18.
6. Ciledag A, Kaya A, Akdogan BB, **Kabalak PA**, Onen ZP, Sen E, Gulbay B. Early use of noninvasive mechanical ventilation in patients with acute hypercapnic respiratory failure in a respiratory ward: a prospective study. Arch Bronconeumol. 2010 Oct;46(10):538-42. doi: 10.1016/j.arbres.2010.06.017. Epub 2010 Aug 13. Spanish.
7. Celik G, Ciledag A, **Akin P**, Simsek Y, Kaya A, Numanoglu N, Saglik YY, Boyvat A, Erekul S. Subcutaneous sarcoidosis with plantar involvement. Ann Dermatol. 2010 Nov;22(4):435-8. doi: 10.5021/ad.2010.22.4.435. Epub 2010 Nov 5.
8. Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.
9. **Akın Kabalak P**, Kızılgöz D, Yılmaz Ü, İnal Cengiz T, Tunç E, Yaman Ş, Gülhan E. Treatment outcomes in oligometastatic non-small-cell lung cancer: A single-centre experience. Clin Respir J. 2020 May;14(5):471-480. doi: 10.1111/crj.13157. Epub 2020 Mar 12.
10. **Kabalak PA**, Kızılgöz D, Kavurgacı S, Demirci NY, Yılmaz Ş, Ak G, Metintaş S, Metintaş M, Demirağ F, Yılmaz Ü. The Clinical Impact of Re-biopsies in Lung Adenocarcinoma: a Retrospective Multicenter Study. Pathol Oncol Res. 2020 Oct;26(4):2703-2708. doi: 10.1007/s12253-020-00876-2. Epub 2020 Jul 13.
11. **Akın Kabalak P**, Yılmaz Ü, Ertürk H, Özmen Ö, Demiröz ŞM, Demirağ F, Kızılgöz D, Kavurgacı S, İnal Cengiz T. Prognostic significance of preoperative consolidation to maximum tumour diameter ratio and SUVmax in pathological stage I lung adenocarcinoma. Clin Respir J. 2020 Feb;14(2):71-77. doi: 10.1111/crj.13102. Epub 2019 Nov 22.
12. Yilmaz S, Demirci NY, Metintas S, Zamani A, Karadag M, Guçlu OA, **Kabalak PA**, Yilmaz U. Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients with Lung Adenocarcinoma: A Multicentric Study. J Occup Environ Med. 2021 Jan 4. doi: 10.1097/JOM.0000000000002115. Online ahead of print.